Study guide

3.4 Stimulants: Intoxication, Crash, and Crisis Risk

IC&RC Alcohol and Drug Counselor CADC

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Orientation, IC&RC ADC Exam, and Credential Path

1.1 ADC Credential, IC&RC, and CADC Naming 1.2 Administering Board Application Workflow 1.3 Minimum Standards and Eligibility Boundaries 1.4 ADC Blueprint and Study Priorities 1.5 Exam Format, Items, and Time Management 1.6 Scores, Results, Retakes, and Remediation 1.7 Exam-Day Admission, In-Person Testing, and Remote Testing

2 Chapter 2: Addiction Science, Substance-Use Patterns, and Risk Factors

2.1 Disease Model and Biopsychosocial Frame 2.2 Reward Pathways, Learning, and Reinforcement 2.3 Tolerance, Withdrawal, Craving, and Cross-Tolerance 2.4 Substance-Use Progression and Severity Patterns 2.5 Risk and Protective Factors Across the Lifespan 2.6 Prevention, Case Conceptualization, and Domain Integration

3 Substance Classes, Intoxication, Overdose, and Withdrawal

3.1 Alcohol Intoxication, Overdose, and Withdrawal 3.2 Sedatives, Hypnotics, Anxiolytics, and Cross-Tolerance 3.3 Opioids: Intoxication, Overdose, and Withdrawal 3.4 Stimulants: Intoxication, Crash, and Crisis Risk 3.5 Cannabis, Hallucinogens, and Inhalants 3.6 Polysubstance Use and Overdose Triage

4 Co-Occurring Mental Health, Medical, and Trauma Concerns

4.1 Co-Occurring Symptoms and Integrated Screening 4.2 Suicide, Self-Harm, and Crisis Triage 4.3 Medical Red Flags and Substance-Related Health Concerns 4.4 Trauma-Informed Care and ACEs 4.5 Special Populations, Developmental, and Cultural Factors 4.6 Scope, Referral, Collaboration, and Documentation

5 Screening, Interviewing, and Assessment Instruments

5.1 Motivational Assessment Interview Stance 5.2 Screening Purpose and Instrument Selection 5.3 Substance-Use History and Pattern Exploration 5.4 Collateral Information and Testing Interpretation 5.5 Risk, Withdrawal, and Immediate Needs Screening 5.6 Engagement, Culture, and Documentation

6 Diagnosis, Biopsychosocial Assessment, and Level of Care

6.1 Diagnostic Concepts and Scope 6.2 Biopsychosocial Assessment Framework 6.3 Immediate and Ongoing Needs 6.4 Level-of-Care Placement Reasoning 6.5 Case Formulation and Assessment Summary 6.6 Documentation, Referral, and Reassessment

7 Counseling Relationship, Communication, and Motivational Interviewing

7.1 Rapport and the Working Alliance 7.2 Core Communication Skills 7.3 OARS and Reflective Listening 7.4 Ambivalence, Resistance, and Discord 7.5 Change Talk and Stages of Change 7.6 Feedback and Counselor Style

8 Treatment Planning, Case Management, and Referral

8.1 Treatment Plan Anatomy 8.2 Individualized Goals and Objectives 8.3 Relapse Prevention and Continuing Care 8.4 Case Management and Resource Linkage 8.5 Referral and Multidisciplinary Collaboration 8.6 Discharge, Termination, and Continuity of Care

9 Group Counseling, Family Work, and Recovery Pathways

9.1 Group Purpose, Screening, and Norms 9.2 Group Stages, Cohesion, and Facilitation Skills 9.3 Psychoeducation, Skills Groups, and Process Groups 9.4 Family and Support-System Collaboration 9.5 Mutual Help, Peer Support, and Recovery Pathways 9.6 Medication, Culture, and Continuing Care

10 Professional Ethics, Boundaries, and Scope of Practice

10.1 Ethical Frameworks and Decision Making 10.2 Boundaries, Dual Relationships, and Power 10.3 Self-Disclosure, Conflicts of Interest, and Gifts 10.4 Scope of Practice, Competence, and Referral 10.5 Supervision, Consultation, and Team Accountability 10.6 Self-Awareness, Impairment, and Burnout

11 Confidentiality, Documentation, Informed Consent, and Client Rights

11.1 Confidentiality Foundations for ADC Practice 11.2 Releases and Minimum Necessary Disclosure 11.3 Documentation and Record Quality 11.4 Informed Consent and Client Rights 11.5 Mandated Reporting and Safety Exceptions 11.6 Grievances, Records, Storage, and Professional Communication

12 Integrated CADC Case Scenarios and Final Review

12.1 Reading Integrated Case Vignettes 12.2 Blueprint-Weighted Final Review 12.3 Integrated Scenario: First Contact Through Assessment 12.4 Integrated Scenario: Treatment, Referral, and Discharge 12.5 Weak-Domain Remediation and 8-12 Week Study Plan 12.6 Exam Day, Results, and Retake Workflow

3.4 Stimulants: Intoxication, Crash, and Crisis Risk

Key Takeaways Explain This Topic AI

Stimulants (cocaine, methamphetamine, prescription amphetamines) activate the CNS; the exam theme is activation, not sedation.

Stimulant overdose is a cardiovascular/neurologic emergency: chest pain, arrhythmia, seizure, stroke, and hyperthermia.

There is no specific antidote like naloxone; stimulant overdose care is supportive, so chest pain or seizure means urgent medical referral.

The post-binge crash brings depression, fatigue, hypersomnia, and intense craving — a window for suicide-risk assessment.

Stimulant withdrawal is rarely medically dangerous but psychologically dangerous; do not equate it with depressant withdrawal.

Last updated: June 2026

Stimulants: activation, not sedation

Stimulants include cocaine , methamphetamine , prescription amphetamines (Adderall, dextroamphetamine) and methylphenidate used outside directions, and related drugs. They flood the brain with dopamine, norepinephrine, and serotonin , so the exam theme is activation : increased energy, pressured speech, reduced sleep, restlessness, irritability, dilated (mydriatic) pupils, sweating, suspiciousness, and inflated confidence. This is the mirror image of the depressant picture — a useful contrast the exam tests directly.

  • Feature Stimulant Opioid/depressant
  • Pupils Dilated (mydriasis) Constricted (miosis, opioids)
  • Energy Increased, agitated Sedated, drowsy
  • Speech Pressured, rapid Slowed, slurred
  • Breathing Rapid Slowed (depressants)
  • Overdose danger Cardiac/neuro/hyperthermia Respiratory depression

Cocaine is short-acting (the high may last under an hour, prompting repeated dosing in a binge); methamphetamine is long-acting (a single use can last many hours), driving days-long sleeplessness sometimes called a "run." At higher risk levels, stimulant use links to panic, paranoia, aggression, risky sex, dehydration, overheating, chest pain, and stimulant-induced psychosis with hallucinations or delusions (classically, the sensation of bugs under the skin — formication, leading to skin-picking sores). Methamphetamine also produces characteristic dental decay ("meth mouth") and weight loss with chronic use.

A crucial pharmacology contrast: cocaine blocks reuptake of dopamine, while amphetamines also force release of dopamine, which is part of why methamphetamine effects are longer and the neurotoxicity concern is greater. The counselor does not need this to prescribe — it explains why the crash, craving, and cognitive effects can be prolonged after methamphetamine.

Stimulant overdose is a different emergency

Unlike opioids, stimulants have no specific reversal agent — overdose care is supportive and medical. The exam wants you to recognize the cardiovascular and neurologic red flags and refer urgently:

  • Overdose red flag Why it matters
  • Chest pain, palpitations Possible heart attack or arrhythmia
  • Severe headache, weakness, slurred speech Possible stroke (hemorrhagic)
  • Seizure Neurologic emergency
  • Hyperthermia (very high body temperature) Major cause of stimulant-overdose death; can lead to organ failure
  • Extreme agitation, paranoia, violence Safety and possible serotonin/sympathetic toxicity

Hyperthermia is a leading contributor to morbidity and mortality in cocaine, amphetamine, and other psychostimulant poisoning and is a hallmark of toxic states. The CADC does not diagnose a cardiac or neurologic event — but recognizes that chest pain, seizure, severe headache, or dangerously high temperature shifts the task from persuasion to urgent medical referral or emergency response .

Applied scenario: a client in group is pacing, has not slept in three days, says people are watching the building, and is sweating heavily. The best answer is not to debate the belief or push insight. A CADC maintains safety, reduces stimulation, consults, and follows crisis or medical referral policy. Paranoia is handled with calm safety steps, never argument. Sweating plus agitation should also prompt concern for hyperthermia, which is the silent killer in stimulant toxicity — a reason this is a medical-referral scenario, not just a behavioral one.

Note that prescription stimulants (used for ADHD) are commonly diverted and misused for studying, weight loss, or performance, so the exam can present a college student or shift worker rather than a stereotyped "street" user. The same activation, crash, and crisis logic applies; legality of the original prescription does not lower the risk.

The crash, craving, and crisis triage

The stimulant crash follows a binge or heavy-use period. The client may sleep for long stretches, feel exhausted and ravenous, become depressed, and experience powerful craving . This is a vulnerable window for return to use and for self-harm — the depressive crash can include hopelessness and suicidal ideation. Stimulant withdrawal/crash is rarely medically dangerous in the depressant sense (no characteristic seizures or DTs), but it is psychologically dangerous , so suicide-risk screening is essential.

Applied scenario: a client reports stopping methamphetamine and now feels empty, ashamed, and unable to get out of bed. The CADC should assess depression and suicide risk, support engagement, and connect the client to mental-health or medical care when indicated. It is still a substance-use counseling context, but the safety screen leads.

Common exam traps:

Treating every stimulant presentation as a motivation problem. Agitation, paranoia, chest pain, or threats shift the task to safety; MI helps after stabilization, not before.

Assuming all withdrawals are equally life-threatening. Alcohol and sedative withdrawal carry seizure/delirium risk; the stimulant crash emphasizes mood, craving, exhaustion, and suicide assessment instead.

Labeling psychosis-like beliefs as "crazy" or "manipulative." Document behavior, not judgments.

Documentation should be behavioral and specific: slept two hours in three days, paced in hallway, stated people outside were following him, endorsed/denied suicidal thoughts, supervisor contacted, referral made. Avoid unsupported labels. There is no FDA-approved medication specifically for stimulant use disorder comparable to opioid MOUD, so the evidence base centers on contingency management and psychosocial treatment — a point the exam may use to test that medication is not the answer for every class.

Stimulants activate the CNS; overdose is cardiac, neurologic, and hyperthermic.

No naloxone-equivalent exists; chest pain or seizure means urgent referral.

The crash brings depression and craving — always screen suicide risk.

Calm safety steps, not argument, address paranoia and psychosis-like states.